Postexposure prophylaxis against experimental inhalation anthrax
- PMID: 8486963
- DOI: 10.1093/infdis/167.5.1239
Postexposure prophylaxis against experimental inhalation anthrax
Abstract
Inhalation anthrax is a rare disease that is almost invariably fatal. This study determined whether a prolonged course of postexposure antibiotics with or without vaccination would protect monkeys exposed to a lethal aerosol dose of Bacillus anthracis when the antibiotic was discontinued. Beginning 1 day after exposure, groups of 10 animals were given penicillin, ciprofloxacin, doxycycline, doxycycline plus vaccination, vaccination alone, or saline. Antibiotics were administered for 30 days and then discontinued. Vaccine was given on days 1 and 15. Two animals died of causes other than anthrax and were not included in the statistical analysis. Nine of 10 controls and 8 of 10 animals given only vaccine died. Each antibiotic regimen completely protected animals while on therapy and provided significant long-term protection upon discontinuance of the drug (penicillin, 7 of 10 survived, P < .02; ciprofloxacin, 8 of 9 survived, P < .002; doxycycline, 9 of 10 survived, P < .002; doxycycline plus vaccination, 9 of 9 survived, P < .0002). Protection against rechallenge was provided by combining postexposure antibiotic treatment with vaccination.
Similar articles
-
Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax.Proc Natl Acad Sci U S A. 2006 May 16;103(20):7813-6. doi: 10.1073/pnas.0602748103. Epub 2006 May 3. Proc Natl Acad Sci U S A. 2006. PMID: 16672361 Free PMC article.
-
A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics.J Infect Dis. 2009 Feb 1;199(3):336-41. doi: 10.1086/596063. J Infect Dis. 2009. PMID: 19099484
-
Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs.Infect Immun. 2002 Nov;70(11):6231-41. doi: 10.1128/IAI.70.11.6231-6241.2002. Infect Immun. 2002. PMID: 12379702 Free PMC article.
-
Postexposure Prophylaxis and Treatment of Bacillus anthracis Infections: A Systematic Review and Meta-analyses of Animal Models, 1947-2019.Clin Infect Dis. 2022 Oct 17;75(Suppl 3):S379-S391. doi: 10.1093/cid/ciac591. Clin Infect Dis. 2022. PMID: 36251546 Free PMC article.
-
The prophylaxis and treatment of anthrax.Int J Antimicrob Agents. 2002 Nov;20(5):320-5. doi: 10.1016/s0924-8579(02)00200-5. Int J Antimicrob Agents. 2002. PMID: 12431866 Review.
Cited by
-
Review: The risk of contracting anthrax from spore-contaminated soil - A military medical perspective.Eur J Microbiol Immunol (Bp). 2020 Jun 5;10(2):29-63. doi: 10.1556/1886.2020.00008. Eur J Microbiol Immunol (Bp). 2020. PMID: 32590343 Free PMC article.
-
Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin.Med Immunol. 2005 Mar 24;4(1):4. doi: 10.1186/1476-9433-4-4. Med Immunol. 2005. PMID: 15790405 Free PMC article.
-
Efficacy of ANTHRASIL (Anthrax Immune Globulin Intravenous (Human)) in rabbit and nonhuman primate models of inhalational anthrax: Data supporting approval under animal rule.PLoS One. 2023 Mar 17;18(3):e0283164. doi: 10.1371/journal.pone.0283164. eCollection 2023. PLoS One. 2023. PMID: 36930692 Free PMC article. Clinical Trial.
-
Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine.Infect Immun. 2004 Jun;72(6):3471-7. doi: 10.1128/IAI.72.6.3471-3477.2004. Infect Immun. 2004. PMID: 15155654 Free PMC article.
-
Passive Immunotherapy Protects against Enteric Invasion and Lethal Sepsis in a Murine Model of Gastrointestinal Anthrax.Toxins (Basel). 2015 Sep 29;7(10):3960-76. doi: 10.3390/toxins7103960. Toxins (Basel). 2015. PMID: 26426050 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical